Vernalis (VER)

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

 45.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 45.50
  • 52 Week Low: 27.25
  • Currency: UK Pounds
  • Shares Issued: 442.27m
  • Volume: 2,960
  • Market Cap: 201.23m
  • RiskGrade: 219
  • Beta: 0.35

Vernalis Overview

Vernalis is in the pharmaceuticals & biotechnology sector and is currently trading at 45.50p per share. In the last year Vernalis's share price has ranged from 27.25p to 45.50p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -40.4% -107.4%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 14.3 18.9
Pr/Book 2.4  
Latest F'cast
Revenue -3.6% -24.3%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Vernalis Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-09 13.02 (14.34) (25.90)p n/a n/a n/a n/a 0.0%
31-Dec-10 14.20 (22.13) (3.00)p n/a n/a n/a n/a 0.0%
31-Dec-11 12.16 (10.61) (6.50)p n/a n/a n/a n/a 0.0%
31-Dec-12 14.62 (6.84) (1.40)p n/a n/a n/a n/a 0.0%
31-Dec-13 14.08 (6.27) (1.30)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Vernalis Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-14 10.66 (11.45) (2.02)p n/a n/a n/a n/a 0.0%
31-Dec-15 13.83 (15.95) (3.04)p n/a n/a n/a n/a 0.0%

Copyright © 2014 FactSet Research Systems Inc. All rights reserved.

Vernalis Company Announcements

FDA accepts TuzistraTM XR NDA for full review 15-Sep-2014 07:00 RNS
Holding(s) in Company 05-Sep-2014 10:30 RNS
Total Voting Rights 29-Aug-2014 16:00 RNS

Latest Vernalis Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Vernalis Market Data

Currency UK Pounds
Share Price 45.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 45.50
52 Week Low 27.25
Volume 2,960
Shares Issued 442.27m
Market Cap 201.23m
Beta 0.35
RiskGrade 219

Vernalis Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
26.82% below the market average26.82% below the market average26.82% below the market average26.82% below the market average26.82% below the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average
Price Trend
93.00% above the market average93.00% above the market average93.00% above the market average93.00% above the market average93.00% above the market average
81.13% above the sector average81.13% above the sector average81.13% above the sector average81.13% above the sector average81.13% above the sector average
Income Not Available
Growth
19.11% below the market average19.11% below the market average19.11% below the market average19.11% below the market average19.11% below the market average
10% below the sector average10% below the sector average10% below the sector average10% below the sector average10% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Vernalis Dividends

No dividends found

Trades for 18-Sep-2014

Time Volume / Share Price
11:08 960 @ 44.49p
10:42 2,000 @ 44.55p

Vernalis Key Personnel

CFO David Mackney
CEO Ian Garland

Top of Page